

#### BRIEF COMMUNICATION

Japan foresees early-stage medical abortion approval: Will this reduce barriers to access safe abortion?

Sumire Sorano<sup>1,2</sup>, Sakiko Emmi<sup>3</sup>, Kazuyo Machiyama<sup>4</sup>, Chris Smith<sup>1,5</sup>

- School of Tropical Medicine and Global Health, Nagasaki University,
   Nagasaki, Japan
- Department of Disease Control, Faculty of Infectious and Tropical Disease,
   London School of Hygiene & Tropical Medicine, London, UK
- Department of Social Psychiatry and Mental Health, Faculty of Medicine,
   University of Tsukuba, Ibaraki, Japan
- 4. Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
- Department of Clinical Research, Faculty of Infectious and Tropical
   Disease, London School of Hygiene & Tropical Medicine, London, UK

## Correspondence

Sumire Sorano, 1–14 Bunkyomachi, Nagasaki, 852-8521, Japan.

Email: soranosumire@gmail.com

### Keywords

medical abortion, safe abortion, sexual and reproductive health and rights

### Synopsis

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ijgo.14226

Approval of medical abortion in Japan may not necessarily improve access to safe abortion, due to the proposed over-medicalized protocol and expensive service fee.

In the past 30 years, since mifepristone was licensed in France in 1988, medical abortion has revolutionized abortion care globally [1]. While medical abortion sometimes (<5%) requires additional intervention to achieve complete abortion [1], compared to surgical abortion which can be completed in a short procedure, it requires fewer resources and is preferred by women who want to avoid surgery or anesthesia. Some women feel that medical abortion is more "natural" [2]. Increasing evidence shows that self-administration of medical abortion with remote support is effective and safe with a high level of patient satisfaction, and is supported by different national and international professional societies including FIGO, the International Federation of Gynecology and Obstetrics [3].

While Japan was one of the first countries to legalize induced abortion in 1948, medical abortion is not approved. Japan still relies on dilatation and curettage (D&C), an invasive method classified as "unsafe" by the World Health Organization (WHO) [4], and shown to have a higher risk of complications compared to other methods in Japan [5]. Given this situation, in July 2021 the Ministry of Health Labor and Welfare requested occupational and academic societies of obstetrics and gynecology to shift to a safer surgical method, vacuum aspiration (VA) [6]. However, the President of the Society of Obstetrics and

Gynecology (JSOG) reported a concern that a "sudden change of the method would rather make it less safe because doctors are not used to practice VA" [6].

In December 2021, a pharmaceutical company filed an application for approval of mifepristone and misoprostol. Once approved, medical abortion will be available in Japan. However, whether it improves women's experience and accessibility depends on the protocol and the price. If a protocol requires each dose of pills to be taken under direct observation and women to stay under facility-based medical supervision until complete abortion, it could rather impose a greater burden on doctors and patients [7]. From an economic perspective, induced abortion is not covered by public health insurance and is operated under private practice, where each provider can set the price. First-trimester abortion, for which surgical method is currently the only option, costs about US\$925–1850 [7]. There are 150 000 abortions each year in Japan [8]. The Japan Association of Obstetricians and Gynecologists (JAOG) reportedly commented that medical abortion pills should be prescribed only by authorized doctors and in facilities with bed capacity and a management fee that is equivalent to that for surgery [9]. These comments made by professional societies raise concerns about the priority of protecting economic interests instead of trying to improve quality of care and women's health.

Women who cannot access abortion care could resort to desperate measures. Indeed, tragic cases are reported where women were arrested after abandoning their newborns after giving birth alone [10]. Approval of medical abortion is

welcome news. However, this may not necessarily translate to greater access to safe abortion care due to the proposed unnecessary protocol and high financial costs women would need to bear.

### **AUTHOR CONTRIBUTIONS**

SE designed the overall structure of manuscript. SS drafted the early version of the manuscript. KM and CS gave comments on the manuscript. All authors edited the manuscript and approved the final version.

# **CONFLICTS OF INTEREST**

SS is supported by WISE Program (Doctoral Program for World-leading Innovative & Smart Education) of Ministry of Education, Culture, Sports, Science and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### REFERENCES

- WHO, "Essential Medicines List Application Mifepristone-Misoprostol for Medical Abortion," 2018. [Online]. Available: https://www.who.int/selection\_medicines/committees/expert/22/applications/s22.1\_mifepristone-misoprostol.pdf.
- Robson SC, Kelly T, Howel D, Deverill M, Hewison J. Randomised preference trial of medical versus surgical termination of pregnancy less than 14 weeks' gestation (TOPS). Health Technol Assess 2009;13(53)
- 3. FIGO. FIGO endorses the permanent adoption of telemedicine abortion

- services, 2021. https://www.figo.org/FIGO-endorses-telemedicine-abortion-services.
- WHO. Preventing Unsafe Abortion, 2020. https://www.who.int/newsroom/fact-sheets/detail/preventing-unsafe-abortion. Accessed November 6, 2021.
- 5. Sekiguchi A, Ikeda T, Okamura K, Nakai A. Safety of induced abortions at less than 12 weeks of pregnancy in Japan. *Int. J. Gynecol. Obstet* 2015; 129: 54–7. doi: 10.1016/j.ijgo.2014.09.032.
- 6. The world's trend toward safer abortion with the suction method: MHLW inform academic societies," Jul. 2021. https://www.tokyo-np.co.jp/article/117804.
- 7. UK pharma firm to seek first Japan approval for abortion pill, but challenges remain," Apr. 2021.

  https://mainichi.jp/english/articles/20210421/p2a/00m/0na/027000c.
- J. Ministry of Health Labor and Welfare. Number of Induced Abortions in 2020. 2021. https://www.mhlw.go.jp/stf/newpage\_18838.html. Accessed August 26, 2021.
- Application filed for approval of use of 'oral abortion pill First non-surgical option in Japan. Dec. 2021.
   https://www3.nhk.or.jp/news/html/20211222/k10013398921000.html.
- 10. Akusawa E. Denied abortion resulted in abandoning infant corpse: Hospitals said 'partner's consent necessary' though it wasn't. Jul. 2021.
  https://digital.asahi.com/articles/ASP6B74N8P63OIPE002.html.